Center for Neurosciences, The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA.
Neuroimage. 2013 Sep;78:204-9. doi: 10.1016/j.neuroimage.2013.03.070. Epub 2013 Apr 8.
Prior evidence has suggested a link between caudate dopaminergic functioning and cognition in Parkinson's disease (PD). In this dual tracer study we analyzed the relationship between nigrostriatal dopaminergic dysfunction and the expression of the previously validated PD cognition-related metabolic pattern (PDCP). In this study, 17 non-demented PD patients underwent positron emission tomography (PET) imaging with [(18)F]-fluorodeoxyglucose to measure PDCP expression, and [(18)F]-fluoropropyl-β-CIT (FPCIT) to measure dopamine transporter (DAT) binding. Automated voxel-by-voxel searches of the FPCIT PET volumes were performed to identify regions in which DAT binding significantly correlated with PDCP expression values. The findings were validated using prespecified anatomical regions-of-interest (ROIs). Voxel-wise interrogation of the FPCIT PET scans revealed a single significant cluster in which DAT binding correlated with PDCP expression (p<0.05, corrected). This cluster was localized to the left caudate nucleus; an analogous correlation (r=-0.63, p<0.01) was also present in the "mirror" region of the right hemisphere. These findings were confirmed by the presence of a significant correlation (r=-0.67, p<0.005) between PDCP expression and DAT binding in caudate ROIs, which survived adjustment for age, disease duration, and clinical severity ratings. Correlation between caudate DAT binding and subject expression of the PD motor-related metabolic pattern was not significant (p>0.21). In summary, this study demonstrates a significant relationship between loss of dopaminergic input to the caudate nucleus and the expression of a cognition-related disease network in unmedicated PD patients. These baseline measures likely function in concert to determine the cognitive effects of dopaminergic therapy in PD.
先前的证据表明,尾状核多巴胺能功能与帕金森病(PD)的认知之间存在关联。在这项双示踪剂研究中,我们分析了黑质纹状体多巴胺能功能障碍与先前验证的与 PD 认知相关的代谢模式(PDCP)表达之间的关系。在这项研究中,17 名非痴呆 PD 患者接受了正电子发射断层扫描(PET)成像,使用[18F]-氟脱氧葡萄糖测量 PDCP 表达,并用[18F]-氟丙基-β-CIT(FPCIT)测量多巴胺转运体(DAT)结合。对 FPCIT PET 体积进行自动体素搜索,以识别 DAT 结合与 PDCP 表达值显著相关的区域。使用预定的解剖学感兴趣区(ROI)验证了这些发现。对 FPCIT PET 扫描进行的体素询问揭示了一个与 PDCP 表达显著相关的单一显著簇(p<0.05,校正)。该簇位于左侧尾状核;在右侧大脑半球的“镜像”区域也存在类似的相关性(r=-0.63,p<0.01)。这些发现通过存在与尾状核 ROI 中 PDCP 表达和 DAT 结合之间的显著相关性(r=-0.67,p<0.005)得到证实,这些相关性在调整年龄、疾病持续时间和临床严重程度评分后仍然存在。尾状核 DAT 结合与 PD 运动相关代谢模式的患者表达之间的相关性不显著(p>0.21)。总之,这项研究表明,未经治疗的 PD 患者中,尾状核多巴胺能传入的丧失与认知相关疾病网络的表达之间存在显著关系。这些基线测量可能协同作用,以确定多巴胺能治疗对 PD 认知的影响。